Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.

Iderberg H, McCreary AC, Varney MA, Kleven MS, Koek W, Bardin L, Depoortère R, Cenci MA, Newman-Tancredi A.

Exp Neurol. 2015 Sep;271:335-50. doi: 10.1016/j.expneurol.2015.05.021. Epub 2015 May 30.

PMID:
26037043
2.

Lobeline Effects on Cognitive Performance in Adult ADHD.

Martin CA, Nuzzo PA, Ranseen JD, Kleven MS, Guenthner G, Williams Y, Walsh SL, Dwoskin LP.

J Atten Disord. 2018 Dec;22(14):1361-1366. doi: 10.1177/1087054713497791. Epub 2013 Aug 21.

3.

Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.

Newman-Tancredi A, Kleven MS.

Psychopharmacology (Berl). 2011 Aug;216(4):451-73. doi: 10.1007/s00213-011-2247-y. Epub 2011 Mar 11. Review.

PMID:
21394633
4.

F15599, a highly selective post-synaptic 5-HT(1A) receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity.

Assié MB, Bardin L, Auclair AL, Carilla-Durand E, Depoortère R, Koek W, Kleven MS, Colpaert F, Vacher B, Newman-Tancredi A.

Int J Neuropsychopharmacol. 2010 Nov;13(10):1285-98. doi: 10.1017/S1461145709991222. Epub 2010 Jan 11.

PMID:
20059805
5.

Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.

Auclair AL, Kleven MS, Barret-Grévoz C, Barreto M, Newman-Tancredi A, Depoortère R.

Behav Brain Res. 2009 Nov 5;203(2):288-95. doi: 10.1016/j.bbr.2009.05.015. Epub 2009 May 21.

PMID:
19464324
6.

F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.

Depoortère R, Bardin L, Auclair AL, Kleven MS, Prinssen E, Colpaert F, Vacher B, Newman-Tancredi A.

Br J Pharmacol. 2007 May;151(2):253-65. Epub 2007 Mar 20.

7.

F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.

Depoortère R, Auclair AL, Bardin L, Bruins Slot L, Kleven MS, Colpaert F, Vacher B, Newman-Tancredi A.

Br J Pharmacol. 2007 May;151(2):266-77. Epub 2007 Mar 20.

8.

Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.

Bardin L, Auclair A, Kleven MS, Prinssen EP, Koek W, Newman-Tancredi A, Depoortère R.

Behav Pharmacol. 2007 Mar;18(2):103-18.

PMID:
17351418
9.

Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.

Auclair AL, Kleven MS, Besnard J, Depoortère R, Newman-Tancredi A.

Neuropsychopharmacology. 2006 Sep;31(9):1900-9. Epub 2006 Jan 18.

10.

Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties.

Bardin L, Kleven MS, Barret-Grévoz C, Depoortère R, Newman-Tancredi A.

Neuropsychopharmacology. 2006 Sep;31(9):1869-79. Epub 2005 Oct 19.

11.

Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat.

Bruins Slot LA, Kleven MS, Newman-Tancredi A.

Neuropharmacology. 2005 Dec;49(7):996-1006. Epub 2005 Jul 11.

PMID:
16009387
12.

Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats.

Kleven MS, Barret-Grévoz C, Bruins Slot L, Newman-Tancredi A.

Neuropharmacology. 2005 Aug;49(2):135-43. Epub 2005 Apr 1.

PMID:
15996562
13.

Anticataleptic properties of alpha2 adrenergic antagonists in the crossed leg position and bar tests: differential mediation by 5-HT1A receptor activation.

Kleven MS, Assié MB, Cosi C, Barret-Grévoz C, Newman-Tancredi A.

Psychopharmacology (Berl). 2005 Feb;177(4):373-80. Epub 2004 Sep 24.

PMID:
15448976
14.

Ability of dopamine antagonists to inhibit the locomotor effects of cocaine in sensitized and non-sensitized C57BL/6 mice depends on the challenge dose.

Prinssen EP, Colpaert FC, Kleven MS, Koek W.

Psychopharmacology (Berl). 2004 Apr;172(4):409-14. Epub 2003 Dec 11.

PMID:
14668976
15.
17.
18.
19.
20.
21.

F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine.

John GW, Pauwels PJ, Perez M, Halazy S, Le Grand B, Verscheure Y, Valentin JP, Palmier C, Wurch T, Chopin P, Marien M, Kleven MS, Koek W, Assie MB, Carilla-Durand E, Tarayre JP, Colpaert FC.

J Pharmacol Exp Ther. 1999 Jul;290(1):83-95.

PMID:
10381763
22.
23.

Does crossing over repeated treatment with the dopamine reuptake inhibitors cocaine and BTCP modify their effects on cocaine-induced locomotion?

Prinssen EP, Koek W, Vignon J, Kamenka JM, Kleven MS.

Psychopharmacology (Berl). 1999 Mar;143(1):8-14.

PMID:
10227073
24.
25.

The cataleptogenic effects of the neuroleptic nemonapride are attenuated by its 5-HT1A receptor agonist properties.

Prinssen EP, Kleven MS, Koek W.

Eur J Pharmacol. 1998 Sep 4;356(2-3):189-92.

PMID:
9774248
26.

F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential.

Koek W, Patoiseau JF, Assié MB, Cosi C, Kleven MS, Dupont-Passelaigue E, Carilla-Durand E, Palmier C, Valentin JP, John G, Pauwels PJ, Tarayre JP, Colpaert FC.

J Pharmacol Exp Ther. 1998 Oct;287(1):266-83.

PMID:
9765347
27.

Cocaine sensitization prevents the hypolocomotor effects of high but not low doses of PD 128,907.

Prinssen EP, Koek W, Kleven MS.

Eur J Pharmacol. 1998 Aug 14;355(1):19-22. Erratum in: Eur J Pharmacol 1998 Nov 20;361(2-3):321.

PMID:
9754934
28.

Discriminative stimulus properties of cocaine: enhancement by monoamine reuptake blockers.

Kleven MS, Koek W.

J Pharmacol Exp Ther. 1998 Mar;284(3):1015-25.

PMID:
9495862
29.
31.

Discriminative stimulus properties of cocaine: enhancement by beta-adrenergic receptor antagonists.

Kleven MS, Koek W.

Psychopharmacology (Berl). 1997 Jun;131(3):307-12.

PMID:
9203242
32.
33.
34.
35.
36.

Parametric analysis of cocaine self-administration under a progressive-ratio schedule in rhesus monkeys.

Rowlett JK, Massey BW, Kleven MS, Woolverton WL.

Psychopharmacology (Berl). 1996 Jun;125(4):361-70.

PMID:
8826541
37.

Repeated administration of cocaethylene induces context-dependent sensitization to its locomotor effects.

Prinssen EP, Kleven MS, Koek W.

Psychopharmacology (Berl). 1996 Apr;124(4):300-5.

PMID:
8739544
38.

Effects of repeated administration of N-[1-(2-benzo(b)-thiophenyl)cyclohexy]piperidine and cocaine on locomotor activity in C57BL/6 mice.

Prinssen EP, Kleven MS, Vignon J, Kamenka JM, Koek W.

J Pharmacol Exp Ther. 1996 Mar;276(3):904-11.

PMID:
8786568
40.
41.
42.

Repeated injection of cocaine potentiates methamphetamine-induced toxicity to dopamine-containing neurons in rat striatum.

Kleven MS, Seiden LS.

Ann N Y Acad Sci. 1992 Jun 28;654:464-6. No abstract available.

PMID:
1632605
43.

Methamphetamine-induced neurotoxicity: structure activity relationships.

Kleven MS, Seiden LS.

Ann N Y Acad Sci. 1992 Jun 28;654:292-301. Review. No abstract available.

PMID:
1632588
44.

Effects of repeated injections of cocaine on catecholamine receptor binding sites, dopamine transporter binding sites and behavior in rhesus monkey.

Farfel GM, Kleven MS, Woolverton WL, Seiden LS, Perry BD.

Brain Res. 1992 Apr 24;578(1-2):235-43.

PMID:
1380862
45.

Assessment of new medications for stimulant abuse treatment.

Woolverton WL, Kleven MS.

NIDA Res Monogr. 1992;119:155-9. Review. No abstract available.

PMID:
1359417
46.

Effects of continuous cocaine administration on schedule-controlled behavior in rhesus monkeys.

Kleven MS, Woolverton WL.

Behav Pharmacol. 1991 Dec;2(6):471-480.

PMID:
11224089
47.
48.
49.

Effects of repeated injections of cocaine on D1 and D2 dopamine receptors in rat brain.

Kleven MS, Perry BD, Woolverton WL, Seiden LS.

Brain Res. 1990 Nov 5;532(1-2):265-70.

PMID:
2149299
50.

Pharmacological characterization of the discriminative stimulus effects of cocaine in rhesus monkeys.

Kleven MS, Anthony EW, Woolverton WL.

J Pharmacol Exp Ther. 1990 Jul;254(1):312-7.

PMID:
2195158

Supplemental Content

Loading ...
Support Center